University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
NCT Number: NCT01262092
This study involves inducting treatment seeking opioid dependent participants onto buprenorphine. Once the participant reaches a stable dose they will receive either placebo or gabapentin to determine if gabapentin helps ease withdrawal symptoms while the participant undergoes a 10-day buprenorphine detoxification.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Little Rock, Arkansas, 72205, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
Other names: Neurontin, Suboxone,
Time frame: 3x weekly during wks 3 and 4
urine data are from those obtained during the buprenorphine taper
University of Arkansas
Other
Acronym: Detox
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04325659
Chemically-Induced Disorders, Mental Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT03789214
Chemically-Induced Disorders, Mental Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT02548728
Chemically-Induced Disorders, Mental Disorders
Chapel Hill, North Carolina, United States
View Trial DetailsNCT03969238
Agnosia, Chemically-Induced Disorders
Charlottesville, Virginia, United States
View Trial Details